A number of experimental treatments are being studied or will undergo trials proximately:[73]
ZMapp, a monoclonal antibody vaccine. The limited supply of the drug has been used to treat a few individuals infected with the Ebola virus: two U.S. aid workers who contracted Ebola in Liberia were successfully treated after repatriation in an Atlanta hospital;[74] a Spanish priest was treated after repatriation but later died; and three infected African doctors, one of whom died in Monrovia on 24 August, also received the experimental drug.[74]
TKM-Ebola, an RNA interference drug.[75]
Favipiravir, a drug approved in Japan for stockpiling against influenza pandemics.[76] The drug appears to be useful in a mouse model of the disease[77][78] and Japan has offered to supply the drug if requested by the WHO.